Literature DB >> 9220453

Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease.

D Offen1, I Ziv, A Barzilai, S Gorodin, E Glater, A Hochman, E Melamed.   

Abstract

The function of neuromelanin (NM), the oxidized dopamine (DA) polymer, within the DA-producing cells in the human and primate substantia nigra (SN), is still an enigma. Some studies show that the vulnerability of nigral neurons in Parkinson's disease is correlated to their toxic NM content, while others suggest that it contributes to cellular protection. We showed recently that DA, the endogenous nigral neurotransmitter, triggers apoptosis, an active program of cellular self-destruction, in neuronal cultures. In the present study, we exposed cells to synthetic dopamine-melanin (DA-M) and analysed the cellular and genetic changes. We found that exposure of PC12 cells to DA-M (0.5 mg/ml for 24 h) caused 50% cell death, as indicated by trypan blue exclusion assay and 3H-thymidine incorporation. Gel electrophoresis DNA analysis of PC12 cells treated with DA-M showed the typical apoptotic DNA ladder, indicating inter-nucleosomal DNA degradation. The DNA fragmentation also was visualized histochemically in situ by DNA end-labeling staining (the TUNEL method). The FeCl2 (0.05 mM) significantly increased DA-M toxicity, while desferrioxamine, an iron chelator, totally abolished the additive toxicity of iron. The contribution of oxidative stress in this model of DA-M-induced cell death was examined using various antioxidants. In contrast to DA, inhibition of DA-M toxicity antioxidants by reduced glutathione (GSH), N-acetyl cysteine, catalase and Zn/Cu superoxide dismutase (SOD) was very limited. In conclusion, we found that DA-M may induce typical apoptotic death in PC12 cells. Our findings support a possible role of NM in the vulnerability of the dopaminergic neural degeneration in Parkinson's disease. The differential protective effect by antioxidants against toxicity of DA and DA-M may have implications for future neuroprotective therapeutic approaches for this common neurological disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220453     DOI: 10.1016/s0197-0186(96)00150-7

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  18 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism.

Authors:  Weihong Feng; Huailing Wei; Geng Tao Liu
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 3.  Functional effects of neuromelanin and synthetic melanin in model systems.

Authors:  K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-05-05       Impact factor: 3.575

4.  Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity.

Authors:  D Offen; P M Beart; N S Cheung; C J Pascoe; A Hochman; S Gorodin; E Melamed; R Bernard; O Bernard
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  Oxidative stress, induced by 6-hydroxydopamine, reduces proteasome activities in PC12 cells: implications for the pathogenesis of Parkinson's disease.

Authors:  Hanoch Elkon; Eldad Melamed; Daniel Offen
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 6.  Is there a rationale for neuroprotection against dopamine toxicity in Parkinson's disease?

Authors:  A Barzilai; E Melamed; A Shirvan
Journal:  Cell Mol Neurobiol       Date:  2001-06       Impact factor: 5.046

7.  Z-ligustilide potentiates the cytotoxicity of dopamine in rat dopaminergic PC12 cells.

Authors:  Hongyi Qi; Jia Zhao; Yifan Han; Allan S Y Lau; Jianhui Rong
Journal:  Neurotox Res       Date:  2012-03-27       Impact factor: 3.911

8.  Neurotoxicity due to o-quinones: neuromelanin formation and possible mechanisms for o-quinone detoxification.

Authors:  F Solano; V J Hearing; J C García-Borrón
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

9.  The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system.

Authors:  J Segura-Aguilar; D Metodiewa; S Baez
Journal:  Neurotox Res       Date:  2001-04       Impact factor: 3.911

10.  Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder.

Authors:  Christine L Miller; Peter Murakami; Ingo Ruczinski; Randal G Ross; Melissa Sinkus; Bernadette Sullivan; Sherry Leonard
Journal:  Schizophr Res       Date:  2009-06-06       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.